Mobile

Assessment of the safety and efficacy of intravenous (10mg/kg) and subcutaneous (300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-002510-36

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Efficacy of intravenous administration of secukinumab compared with subcutaneous administration of secukinumab with respect to both PASI 75 and IGA 0 or 1 response

Critère d'inclusion

  • Moderate to severe chronic plaque-type psoriasis

Liens